Type 2 diabetes (T2D) is a complex disease that affects many body systems over time. New treatment options and combinations have proven benefits in reducing diabetes-related complications, in addition to their glucose-lowering effects.
GLP-1 receptor agonists (GLP-1RAs) comprise another tool in the GP’s toolbox to optimise glycaemic control while accommodating for comorbidities such as elevated cardiovascular risk and body weight.
New PBS reimbursement criteria mean that co-administration of weekly GLP-1RAs and insulin is now possible, presenting a powerful new treatment combination for complex patients.
This program will give you the skills and knowledge to identify patient groups who may benefit from concomitant use of weekly GLP-1RAs and insulin, and to prescribe GLP-1RAs with safety and efficacy in mind.
This program is supported by an independent educational grant provided from Eli Lilly.